학술논문
信迪利单抗联合化疗对晚期胃癌患者近期疗效及血清CEA sTim-3 sLAG-3和T淋巴细胞亚群的影响 / Effects of Sintilimab Combined with Chemotherapy on Short-Term Efficacy and Serum CEA,sTim-3 sLAG-3 and T Lymphocyte Subsets in Patients with Advanced Gastric Cancer
Document Type
Academic Journal
Author
Source
河北医学 / Hebei Medicine. 30(2):335-340
Subject
Language
Chinese
ISSN
1006-6233
Abstract
目的:探究信迪利单抗联合化疗对晚期胃癌患者近期疗效及血清癌胚抗原(CEA)、免疫功能和T淋巴细胞亚群的影响.方法:研究样本选取我院2020 年5 月至2022 年5 月就诊84 例晚期胃癌患者,分组方式为分段随机化法(观察组和对照组),每组各 42 例.对照组采用常规化疗进行处理,观察组加用信迪利单抗,两组均持续治疗3 个疗程(3 个月).记录两组患者化疗1 个月后临床效果、治疗期间毒副反应发生情况,比较两组治疗前、治疗 3 疗程后血清肿瘤标志物[糖链抗原(CA)、癌胚抗原(CEA)、MG抗原(MG-Ag)]、免疫功能(sTim-3、sLAG-3)、T 淋巴细胞水平(CD3+、CD4+、CD8+)的变化.治疗后随访1年,记录两组生存率.结果:化疗1个月后,观察组临床有效率高于对照组,毒副作用发生情况无明显差异(P>0.05).治疗 3 疗程后两组 CA、CEA、MG-Ag、sTim-3、sLAG-3 水平显著降低,且观察组低于对照组(P 均<0.05),两组 CD3+、CD4+均降低,且观察组高于对照组,CD8+均升高,且观察组低于对照组(P 均<0.05).观察组 1 年生存率显著高于对照组(P<0.05).结论:信迪利单抗联合化疗对晚期胃癌患者近期疗效显著且安全性较高,可有效改善患者免疫功能,减轻肿瘤负荷.
Objective:To investigate the effects of Sintilimab combined with chemotherapy on short-term efficacy and serum carcinoembryonic antigen(CEA),immune function,and T lymphocyte subsets in pa-tients with advanced gastric cancer.Methods:A total of 84 patients with advanced gastric cancer treated from May 2020 to May 2022 were randomly divided into an observation group and a control group(42 cases each).The control group received conventional chemotherapy,while the observation group received additional Sintil-imab.Both groups underwent three cycles of continuous treatment(3 months).Clinical outcomes after 1 month of chemotherapy,occurrence of toxicities,and changes in serum tumor markers(CA,CEA,MG-Ag),immune function(sTim-3,sLAG-3),and T lymphocyte subsets(CD3+,CD4+,CD8+)were compared be-tween the two groups before and after 3 cycles of treatment.The 1-year survival rate was recorded during fol-low-up.Results:After 1 month of chemotherapy,the observation group showed a higher clinical effective rate compared to the control group,with no significant differences in toxicities(P>0.05).After 3 cycles of treat-ment,both groups exhibited significant reductions in CA,CEA,MG-Ag,sTim-3,and sLAG-3 levels,and the observation group had lower levels than the control group(all P<0.05),CD3+ and CD4+ levels de-creased,with the observation group higher than the control group,while CD8+ levels increased,and the obser-vation group had lower levels than the control group(all P<0.05).The 1-year survival rate in the observa-tion group was significantly higher than in the control group(P<0.05).Conclusion:Sintilimab combined with chemotherapy demonstrates significant short-term efficacy,high safety,and the ability to improve im-mune function in patients with advanced gastric cancer,thereby alleviating the tumor burden.
Objective:To investigate the effects of Sintilimab combined with chemotherapy on short-term efficacy and serum carcinoembryonic antigen(CEA),immune function,and T lymphocyte subsets in pa-tients with advanced gastric cancer.Methods:A total of 84 patients with advanced gastric cancer treated from May 2020 to May 2022 were randomly divided into an observation group and a control group(42 cases each).The control group received conventional chemotherapy,while the observation group received additional Sintil-imab.Both groups underwent three cycles of continuous treatment(3 months).Clinical outcomes after 1 month of chemotherapy,occurrence of toxicities,and changes in serum tumor markers(CA,CEA,MG-Ag),immune function(sTim-3,sLAG-3),and T lymphocyte subsets(CD3+,CD4+,CD8+)were compared be-tween the two groups before and after 3 cycles of treatment.The 1-year survival rate was recorded during fol-low-up.Results:After 1 month of chemotherapy,the observation group showed a higher clinical effective rate compared to the control group,with no significant differences in toxicities(P>0.05).After 3 cycles of treat-ment,both groups exhibited significant reductions in CA,CEA,MG-Ag,sTim-3,and sLAG-3 levels,and the observation group had lower levels than the control group(all P<0.05),CD3+ and CD4+ levels de-creased,with the observation group higher than the control group,while CD8+ levels increased,and the obser-vation group had lower levels than the control group(all P<0.05).The 1-year survival rate in the observa-tion group was significantly higher than in the control group(P<0.05).Conclusion:Sintilimab combined with chemotherapy demonstrates significant short-term efficacy,high safety,and the ability to improve im-mune function in patients with advanced gastric cancer,thereby alleviating the tumor burden.